



US009125718B2

(12) **United States Patent**
Augarten

(10) **Patent No.:** **US 9,125,718 B2**
(45) **Date of Patent:** **Sep. 8, 2015**

(54) **ELECTRONICALLY ENHANCED ACCESS
PORT FOR A FLUID FILLED IMPLANT**

(71) Applicant: **Apollo Endosurgery, Inc.**, Austin, TX
(US)

(72) Inventor: **Mike Augarten**, Goleta, CA (US)

(73) Assignee: **APOLLO ENDOSURGERY, INC.**,
Austin, TX (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/923,076**

(22) Filed: **Jun. 20, 2013**

(65) **Prior Publication Data**

US 2013/0281773 A1 Oct. 24, 2013

Related U.S. Application Data

(63) Continuation of application No. 12/873,096, filed on
Aug. 31, 2010, now abandoned.

(60) Provisional application No. 61/330,266, filed on Apr.
30, 2010.

(51) **Int. Cl.**
A61F 5/00 (2006.01)
A61M 39/02 (2006.01)
A61F 2/04 (2013.01)

(52) **U.S. Cl.**
CPC **A61F 5/0059** (2013.01); **A61F 2/04**
(2013.01); **A61F 5/003** (2013.01); **A61F**
5/0013 (2013.01); **A61F 5/0056** (2013.01);
A61M 39/0208 (2013.01); **A61M 2039/0226**
(2013.01); **A61M 2039/0238** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC A61F 5/0059; A61F 5/003; A61F 5/0056;

A61F 5/0013; A61F 2/04; A61M 39/0208;
A61M 2039/0238; A61M 2039/0226; A61M
2039/0063; A61M 2039/0244; A61M
2205/215; A61M 2205/82; A61M 2205/583;
A61M 2210/1053

USPC 600/37
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

586,113 A 7/1897 Bott
2,163,048 A 6/1939 McKee

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1250382 A 4/2000
CN 1367670 A 9/2002

(Continued)

OTHER PUBLICATIONS

<http://en.wikipedia.org/wiki/Injection.sub.—molding>, dated: Mar.
20, 2014.

(Continued)

Primary Examiner — Jacqueline Cheng


Assistant Examiner — Kaylee Wilson

(74) *Attorney, Agent, or Firm* — Gordon & Jacobson, PC

(57) **ABSTRACT**

The present invention provides for an access port configured
to detect its tilt within the body to facilitate a physician's
access thereto. The access port can include a tilt detector to
detect tilt datum, and a display screen to display the tilt of the
access port. In addition, the tilt detector and the display screen
can indicate whether the access port is flipped or not. The tilt
detector can include an accelerometer to aid in determining
the tilt of the access port.

21 Claims, 7 Drawing Sheets



US 9,125,718 B2

Page 2

(52) U.S. Cl.

CPC ... *A61M 2205/215* (2013.01); *A61M 2205/583*
(2013.01); *A61M 2205/82* (2013.01); *A61M*
2210/1053 (2013.01)

(56)

References Cited

U.S. PATENT DOCUMENTS

2,737,954	A	3/1956	Knapp	5,108,377	A	4/1992	Cone
3,371,352	A	3/1968	Siposs	5,125,408	A	6/1992	Basser
3,569,660	A	3/1971	Houldcroft	5,133,753	A	7/1992	Bark
3,587,115	A	6/1971	Shiley	5,137,529	A	8/1992	Watson
3,596,660	A	8/1971	Melone	5,147,483	A	9/1992	Melsky
3,667,081	A	6/1972	Burger	5,152,747	A	10/1992	Olivier
3,688,764	A	9/1972	Reed	5,167,638	A	12/1992	Felix
3,731,352	A	5/1973	Okamoto	5,185,003	A	2/1993	Brethauer
3,840,018	A	10/1974	Heifetz	5,207,644	A	5/1993	Strecker
3,958,562	A	5/1976	Hakim	5,213,574	A	5/1993	Tucker
3,971,376	A	7/1976	Wichterle	5,226,429	A	7/1993	Kuzmak
4,019,499	A	4/1977	Fitzgerald	5,226,894	A	7/1993	Haber
4,118,805	A	10/1978	Reimels	5,250,026	A	10/1993	Ehrlich
4,151,835	A	5/1979	Copeland	5,273,537	A	12/1993	Haskvitz
4,161,943	A	7/1979	Nogier	5,281,205	A	1/1994	McPherson
4,164,943	A	8/1979	Hill	5,284,479	A	2/1994	de Jong
4,190,040	A	2/1980	Schulte	5,318,545	A	6/1994	Tucker
4,233,992	A	11/1980	Bisping	5,336,194	A	8/1994	Polaschegg
4,265,252	A	5/1981	Chubbuck	5,337,747	A	8/1994	Neftel
4,280,722	A	7/1981	Guptil	5,360,407	A	11/1994	Leonard
4,413,985	A	11/1983	Wellner	5,368,040	A	11/1994	Carney
4,474,572	A	10/1984	McNaughton	5,387,192	A	2/1995	Glantz
4,502,335	A	3/1985	Wamstad	5,391,164	A	2/1995	Giampapa
4,543,088	A	9/1985	Bootman	5,449,368	A	9/1995	Kuzmak
4,557,722	A	12/1985	Harris	5,476,460	A	12/1995	Montalvo
4,569,675	A	2/1986	Prosl	5,514,174	A	5/1996	Heil
4,588,394	A	5/1986	Schulte	5,540,648	A	7/1996	Yoon
4,592,339	A	6/1986	Kuzmak	5,556,388	A	9/1996	Johlin
4,592,355	A	6/1986	Antebi	5,558,641	A	9/1996	Glantz
4,634,427	A	1/1987	Hannula	5,562,617	A	10/1996	Finch
4,655,765	A	4/1987	Swift	5,571,104	A	11/1996	Li
4,673,394	A	6/1987	Fenton	5,575,777	A	11/1996	Cover
4,692,146	A	9/1987	Hilger	5,601,604	A	2/1997	Vincent
4,696,288	A	9/1987	Kuzmak	5,637,102	A	6/1997	Tolkoff
4,704,103	A	11/1987	Stoeber	5,653,755	A	8/1997	Ledergerber
4,710,174	A	12/1987	Moden	5,658,298	A	8/1997	Vincent
4,738,657	A	4/1988	Hancock	5,674,397	A	10/1997	Pawlak
4,767,410	A	8/1988	Moden	5,683,447	A	11/1997	Bush
4,772,270	A	9/1988	Wiita	5,688,237	A	11/1997	Rozga
4,778,452	A	10/1988	Moden	5,695,490	A	12/1997	Flaherty
4,781,680	A	11/1988	Redmond	5,716,342	A	2/1998	Dumbraveanu
4,796,641	A	1/1989	Mills	5,718,682	A	2/1998	Tucker
4,802,885	A	2/1989	Weeks	5,722,957	A	3/1998	Steinbach
4,832,054	A	5/1989	Bark	5,748,200	A	5/1998	Funahashi
4,840,615	A	6/1989	Hancock	5,810,735	A	9/1998	Halperin
4,850,227	A	7/1989	Luetngen	5,814,019	A	9/1998	Steinbach
4,858,623	A	8/1989	Bradshaw	5,833,654	A	11/1998	Powers
4,861,341	A	8/1989	Woodburn	5,843,033	A	12/1998	Ropiak
4,881,939	A	11/1989	Newman	RE36,176	E	3/1999	Kuzmak
4,886,501	A	12/1989	Johnston	5,883,654	A	3/1999	Katsuyama
4,902,278	A	2/1990	Maget	5,902,598	A	5/1999	Chen
4,904,241	A	2/1990	Bark	5,906,596	A	5/1999	Tallarida
4,913,702	A	4/1990	Yum	5,910,149	A	6/1999	Kuzmak
4,915,690	A	4/1990	Cone	5,911,704	A	6/1999	Humes
4,929,230	A	5/1990	Pfleger	5,931,829	A	8/1999	Burbank
4,929,236	A	5/1990	Sampson	5,932,460	A	8/1999	Mills
4,959,752	A	9/1990	Samarov	5,935,083	A	8/1999	Williams
4,966,588	A	10/1990	Rayman	5,938,669	A	8/1999	Klaiber
4,967,755	A	11/1990	Pohndorf	5,951,512	A	9/1999	Dalton
4,978,338	A	12/1990	Melsky	6,024,704	A	2/2000	Meador
5,006,115	A	4/1991	McDonald	6,030,369	A	2/2000	Engelson
5,013,298	A	5/1991	Moden	6,039,712	A	3/2000	Fogarty
5,026,344	A	6/1991	Dijkstra	6,074,341	A	6/2000	Anderson
5,041,098	A	8/1991	Loiterman	6,090,066	A	7/2000	Schnell
5,045,060	A	9/1991	Melsky	6,098,405	A	8/2000	Miyata
5,074,868	A	12/1991	Kuzmak	6,102,678	A	8/2000	Peclat
5,090,954	A	2/1992	Geary	6,102,922	A	8/2000	Jakobsson
5,092,897	A	3/1992	Forte	6,123,700	A	9/2000	Mills
5,094,244	A	3/1992	Callahan	6,152,885	A	11/2000	Taepke
				6,171,252	B1	1/2001	Roberts
				6,183,449	B1	2/2001	Sibbitt
				6,213,973	B1	4/2001	Eliassen
				6,221,024	B1	4/2001	Miesel
				6,234,973	B1	5/2001	Meador
				6,258,079	B1	7/2001	Burbank
				6,264,676	B1	7/2001	Gellman
				6,270,475	B1	8/2001	Bestetti
				6,283,949	B1	9/2001	Roorda
				6,316,734	B1	11/2001	Yang

US 9,125,718 B2

Page 3

(56)

References Cited

U.S. PATENT DOCUMENTS

6,321,124	B1	11/2001	Cigaina	7,591,185	B1	9/2009	Mothilal
6,349,740	B1	2/2002	Cho	7,593,777	B2	9/2009	Gerber
6,432,040	B1	8/2002	Meah	7,634,319	B2	12/2009	Schneider
6,447,550	B1	9/2002	Hunter	7,651,483	B2	1/2010	Byrum
6,450,946	B1	9/2002	Forsell	7,658,196	B2	2/2010	Ferreri
6,453,907	B1	9/2002	Forsell	7,699,770	B2	4/2010	Hassler
6,454,699	B1	9/2002	Forsell	7,708,722	B2	5/2010	Glenn
6,459,917	B1	10/2002	Gowda	7,762,998	B2	7/2010	Birk
6,461,293	B1	10/2002	Forsell	7,762,999	B2	7/2010	Byrum
6,464,628	B1	10/2002	Forsell	7,775,215	B2	8/2010	Hassler
6,470,213	B1	10/2002	Alley	7,775,966	B2	8/2010	Dlugos
6,470,892	B1	10/2002	Forsell	7,811,275	B2	10/2010	Birk
6,478,783	B1	11/2002	Moorehead	7,850,660	B2	12/2010	Uth
6,511,490	B2	1/2003	Robert	7,862,546	B2	1/2011	Conlon
6,547,801	B1	4/2003	Dargent	7,909,754	B2	3/2011	Hassler
6,572,587	B2	6/2003	Lerman	7,909,804	B2	3/2011	Stats
6,589,184	B2	7/2003	Noren	8,007,474	B2	8/2011	Uth
6,648,849	B2	11/2003	Tenhuisen	2001/0052141	A1	12/2001	Andersen
6,666,845	B2	12/2003	Hooper	2002/0013545	A1	1/2002	Soltanpour
6,689,100	B2	2/2004	Connelly	2002/0058969	A1	5/2002	Noren
6,723,053	B2	4/2004	Ackerman	2002/0087147	A1	7/2002	Hooper
6,733,519	B2	5/2004	Lashinski	2002/0095181	A1	7/2002	Beyar
6,792,309	B1	9/2004	Noren	2002/0139208	A1	10/2002	Yatskov
6,810,880	B1	11/2004	Jennings	2002/0198548	A1	12/2002	Robert
6,813,964	B1	11/2004	Clark	2003/0045800	A1	3/2003	Noren
6,860,857	B2	3/2005	Noren	2003/0045910	A1	3/2003	Sorensen
6,915,162	B2	7/2005	Noren	2003/0073880	A1	4/2003	Polsky
6,921,267	B2	7/2005	van Oostrom et al.	2003/0078506	A1	4/2003	Noren
6,929,631	B1	8/2005	Brugger	2003/0139690	A1	7/2003	Aebli
6,939,299	B1	9/2005	Petersen	2003/0194710	A1	10/2003	Yang
6,953,444	B2	10/2005	Rosenberg	2004/0064110	A1	4/2004	Forsell
6,964,204	B2	11/2005	Clark	2004/0065615	A1	4/2004	Hooper
6,966,875	B1	11/2005	Longobardi	2004/0068233	A1	4/2004	DiMatteo
6,997,914	B2	2/2006	Smith	2004/0082908	A1	4/2004	Whitehurst
7,017,583	B2	3/2006	Forsell	2004/0111050	A1	6/2004	Smedley
7,020,531	B1	3/2006	Colliou	2004/0127807	A1*	7/2004	Hatlesad et al. 600/529
7,056,286	B2	6/2006	Ravenscroft	2004/0204692	A1	10/2004	Eliassen
7,063,669	B2	6/2006	Brawner	2004/0213951	A1	10/2004	Shimokawa
7,073,387	B2	7/2006	Zdeblick	2004/0254536	A1	12/2004	Conlon
7,082,843	B2	8/2006	Clark	2004/0254537	A1	12/2004	Conlon
7,118,693	B2	10/2006	Glatkowski	2004/0260229	A1	12/2004	Meir
7,131,945	B2	11/2006	Fink	2004/0260319	A1	12/2004	Egle
7,144,400	B2	12/2006	Byrum	2004/0267288	A1	12/2004	Byrum
7,149,587	B2	12/2006	Wardle	2004/0267291	A1	12/2004	Byrum
7,191,007	B2	3/2007	Desai	2004/0267292	A1	12/2004	Byrum
7,195,774	B2	3/2007	Carvalho	2004/0267293	A1	12/2004	Byrum
7,223,239	B2	5/2007	Schulze	2004/0267377	A1	12/2004	Egle
7,226,419	B2	6/2007	Lane	2005/0010177	A1	1/2005	Tsai
7,261,003	B2	8/2007	McDonald	2005/0049578	A1	3/2005	Tu
7,267,645	B2	9/2007	Anderson	2005/0070875	A1	3/2005	Kulesa
7,282,023	B2	10/2007	Frering	2005/0070937	A1	3/2005	Jambor
7,311,716	B2	12/2007	Byrum	2005/0085778	A1	4/2005	Parks
7,311,717	B2	12/2007	Egle	2005/0092093	A1	5/2005	Kang
7,351,198	B2	4/2008	Byrum	2005/0131325	A1	6/2005	Chen
7,351,226	B1	4/2008	Herskowitz	2005/0131352	A1	6/2005	Conlon
7,351,240	B2	4/2008	Hassler	2005/0131383	A1	6/2005	Chen
7,353,747	B2	4/2008	Swayze	2005/0148956	A1	7/2005	Conlon
7,364,542	B2	4/2008	Jambor	2005/0149143	A1	7/2005	Libbus
7,367,937	B2	5/2008	Jambor	2005/0209573	A1	9/2005	Brugger
7,374,557	B2	5/2008	Conlon	2005/0240155	A1	10/2005	Conlon
7,374,565	B2	5/2008	Hassler	2005/0240156	A1	10/2005	Conlon
7,390,294	B2	6/2008	Hassler	2005/0244453	A1	11/2005	Stucke
7,413,547	B1	8/2008	Lichtscheidl	2005/0267500	A1	12/2005	Hassler
7,416,528	B2	8/2008	Crawford	2005/0277899	A1	12/2005	Conlon
7,437,951	B2	10/2008	McDonald	2005/0283041	A1	12/2005	Egle
7,438,718	B2	10/2008	Milliman	2005/0283118	A1	12/2005	Uth
7,445,614	B2	11/2008	Bunodiene	2005/0283119	A1	12/2005	Uth
7,468,038	B2	12/2008	Ye	2006/0074439	A1	4/2006	Garner
7,500,944	B2	3/2009	Byrum	2006/0122578	A1	6/2006	Lord
7,510,530	B2	3/2009	Hashimoto	2006/0161186	A1	7/2006	Hassler
7,530,943	B2	5/2009	Lechner	2006/0173423	A1	8/2006	Conlon
7,553,298	B2	6/2009	Hunt	2006/0173424	A1	8/2006	Conlon
7,561,916	B2	7/2009	Hunt	2006/0178647	A1	8/2006	Stats
7,563,255	B2	7/2009	Adamis	2006/0178648	A1	8/2006	Barron
7,580,746	B2	8/2009	Gilkerson	2006/0184141	A1	8/2006	Smith
				2006/0189887	A1	8/2006	Hassler
				2006/0189888	A1	8/2006	Hassler
				2006/0190039	A1	8/2006	Birk
				2006/0199997	A1	9/2006	Hassler

(56)

References Cited

U.S. PATENT DOCUMENTS

2006/0211912	A1	9/2006	Dlugos	2009/0076466	A1	3/2009	Quebbemann
2006/0211913	A1	9/2006	Dlugos	2009/0082757	A1	3/2009	Rogers
2006/0211914	A1	9/2006	Hassler	2009/0082793	A1	3/2009	Birk
2006/0217668	A1	9/2006	Schulze	2009/0093768	A1	4/2009	Conlon
2006/0217673	A1	9/2006	Schulze	2009/0099538	A1	4/2009	Paganon
2006/0225274	A1	10/2006	Greenberg	2009/0105735	A1	4/2009	Stam
2006/0235445	A1	10/2006	Birk	2009/0112308	A1	4/2009	Kassem
2006/0235448	A1	10/2006	Roslin	2009/0118572	A1	5/2009	Lechner
2006/0247539	A1	11/2006	Schugt	2009/0149874	A1	6/2009	Ortiz
2006/0266128	A1	11/2006	Clark	2009/0157106	A1	6/2009	Marcotte
2006/0293625	A1	12/2006	Hunt	2009/0157107	A1	6/2009	Kierath
2006/0293626	A1	12/2006	Byrum	2009/0157113	A1	6/2009	Marcotte
2006/0293627	A1	12/2006	Byrum	2009/0171375	A1	7/2009	Coe
2006/0293628	A1	12/2006	Hunt	2009/0171378	A1	7/2009	Coe
2007/0010790	A1	1/2007	Byrum	2009/0171379	A1	7/2009	Coe
2007/0015954	A1	1/2007	Dlugos	2009/0192404	A1	7/2009	Ortiz
2007/0015955	A1	1/2007	Tsonton	2009/0192415	A1	7/2009	Ortiz
2007/0016231	A1	1/2007	Jambor	2009/0192533	A1	7/2009	Dlugos
2007/0027356	A1	2/2007	Ortiz	2009/0192534	A1	7/2009	Ortiz
2007/0038255	A1	2/2007	Kieval	2009/0192541	A1	7/2009	Ortiz
2007/0060959	A1	3/2007	Salo	2009/0198261	A1	8/2009	Schweikert
2007/0073250	A1	3/2007	Schneider	2009/0202387	A1	8/2009	Dlugos
2007/0078391	A1	4/2007	Wortley	2009/0204131	A1	8/2009	Ortiz
2007/0088336	A1	4/2007	Dalton	2009/0204132	A1	8/2009	Ortiz
2007/0088391	A1	4/2007	McAlexander	2009/0209995	A1	8/2009	Byrum
2007/0129765	A1	6/2007	Gilkerson	2009/0216255	A1	8/2009	Coe
2007/0135758	A1	6/2007	Childers	2009/0221974	A1	9/2009	Paganon
2007/0149947	A1	6/2007	Byrum	2009/0222031	A1	9/2009	Axelsson
2007/0156013	A1 *	7/2007	Birk	2009/0222065	A1	9/2009	Dlugos
2007/0158769	A1	7/2007	You	2009/0227862	A1	9/2009	Smith
2007/0160743	A1	7/2007	Babitt	2009/0228028	A1	9/2009	Coe
2007/0161958	A1	7/2007	Glenn	2009/0228072	A1	9/2009	Coe
2007/0167672	A1	7/2007	Dlugos	2009/0234273	A1 *	9/2009	Intoccia et al. 604/22
2007/0173685	A1	7/2007	Jambor	2009/0234302	A1 *	9/2009	Hoendervoogt et al. 604/288.01
2007/0185462	A1	8/2007	Byrum	2009/0248125	A1	10/2009	Brostrom
2007/0191717	A1	8/2007	Rosen	2009/0248126	A1	10/2009	Nippoldt
2007/0205384	A1	9/2007	Kurosawa	2009/0254052	A1	10/2009	Birk
2007/0208313	A1	9/2007	Conlon	2009/0259190	A1	10/2009	Birk
2007/0213837	A1 *	9/2007	Ferreri et al. 623/23.65	2009/0259191	A1	10/2009	Birk
2007/0219510	A1	9/2007	Zinn	2009/0259231	A1	10/2009	Birk
2007/0235083	A1	10/2007	Dlugos	2009/0264901	A1	10/2009	Franklin
2007/0238992	A1 *	10/2007	Donofrio et al. 600/437	2009/0270904	A1	10/2009	Birk
2007/0250086	A1	10/2007	Wiley	2009/0299216	A1	12/2009	Chen
2007/0255165	A1	11/2007	Uesugi	2009/0299672	A1	12/2009	Zhang
2007/0255234	A1	11/2007	Haase	2009/0306462	A1	12/2009	Lechner
2007/0265645	A1	11/2007	Birk	2009/0308169	A1	12/2009	Mothilal
2007/0265666	A1	11/2007	Roberts	2009/0317443	A1	12/2009	Willis
2007/0282196	A1	12/2007	Birk	2010/0087843	A1	4/2010	Bertolote
2007/0293829	A1	12/2007	Conlon	2010/0100079	A1	4/2010	Berkcan
2008/0009680	A1	1/2008	Hassler	2010/0114149	A1	5/2010	Albrecht
2008/0015406	A1	1/2008	Dlugos	2010/0130941	A1	5/2010	Conlon
2008/0039772	A1	2/2008	Chantriaux	2010/0152532	A1	6/2010	Marcotte
2008/0058632	A1	3/2008	Tai	2010/0191271	A1	7/2010	Lau
2008/0097496	A1	4/2008	Chang	2010/0211085	A1	8/2010	Uth
2008/0114308	A1	5/2008	di Palma et al.	2010/0217198	A1	8/2010	Franklin
2008/0119798	A1	5/2008	Chantriaux	2010/0217199	A1	8/2010	Uth
2008/0243093	A1	10/2008	Kalpin	2010/0217200	A1	8/2010	Uth
2008/0249806	A1	10/2008	Dlugos	2010/0228080	A1	9/2010	Tavori
2008/0250340	A1	10/2008	Dlugos	2010/0234808	A1	9/2010	Uth
2008/0250341	A1	10/2008	Dlugos	2010/0286766	A1	11/2010	Ye
2008/0255403	A1	10/2008	Voegelé	2011/0054407	A1	3/2011	Olroyd
2008/0255414	A1	10/2008	Voegelé	2011/0082426	A1	4/2011	Conlon
2008/0255425	A1	10/2008	Voegelé				
2008/0255459	A1	10/2008	Voegelé				
2008/0255537	A1	10/2008	Voegelé				
2008/0281412	A1	11/2008	Smith				
2008/0287969	A1	11/2008	Tsonton				
2008/0287974	A1	11/2008	Widenhouse				
2008/0312553	A1	12/2008	Timmons				
2008/0319435	A1	12/2008	Rioux				
2009/0018608	A1	1/2009	Schwartz				
2009/0048524	A1	2/2009	Wildau				
2009/0054914	A1	2/2009	Lechner				
2009/0062825	A1	3/2009	Pool				
2009/0071258	A1	3/2009	Kouda				

FOREIGN PATENT DOCUMENTS

DE	3927001	2/1991
DE	4211045	10/1993
DE	19745654	4/1999
DE	19751791	5/1999
EP	0343910	A2 11/1989
EP	0611561	8/1994
EP	0858814	8/1998
EP	0867197	9/1998
EP	1057457	12/2000
EP	1346753	9/2003
EP	1396242	A1 3/2004
EP	1396243	A1 3/2004
EP	1488824	A1 12/2004
EP	1543861	A1 6/2005

(56)

References Cited

FOREIGN PATENT DOCUMENTS

EP	1547643	6/2005
EP	1591140 A1	11/2005
EP	1736194 A1	12/2006
EP	1736195	12/2006
EP	1736196	12/2006
EP	1736197	12/2006
EP	1736198	12/2006
EP	1736199	12/2006
EP	1870126	12/2007
EP	1985263	10/2008
EP	2070494 A1	6/2009
EP	2095798	9/2009
FR	2740977	5/1997
FR	2797181 A1	2/2001
FR	2823663 A1	10/2002
FR	2851168	8/2004
FR	2855744 A1	12/2004
FR	2916980	12/2008
JP	2119877	5/1990
JP	8107934	4/1996
SU	1823791	6/1991
WO	9220519 A1	11/1992
WO	9422520	10/1994
WO	9640357	12/1996
WO	9701370	1/1997
WO	9920338	4/1999
WO	9926543	6/1999
WO	9934859	7/1999

WO	0015158 A1	3/2000
WO	0033901	6/2000
WO	0110359 A1	2/2001
WO	0149245 A2	7/2001
WO	0180926	11/2001
WO	0195813 A1	12/2001
WO	0210667 A2	2/2002
WO	02074381	9/2002
WO	03105732 A1	12/2003
WO	2004016971	2/2004
WO	2005037055 A2	4/2005
WO	2005072627 A1	8/2005
WO	2006021695	3/2006
WO	2009007526	1/2009
WO	2009129474 A1	10/2009

OTHER PUBLICATIONS

Autumn K. et al.; 'Evidence of Van Der Waals Adhesion in Gecko Setae'; PNAS; vol. 99; No. 19; pp. 12252-12256; Sep. 17, 2012.

Geim AK. et al.; 'Microfabricated Adhesive Mimicking Gecko Foot-Hair'; Nature Materials Abstract only; vol. 2; No. 7; 2003.

Yamagami, Takuji; 'Technical Developments; Use of Targeting Guide Wire in Left Subclavian Puncture During Percutaneous Implantation of Port-Catheter Systems Using the Catheter Tip Fixation Method' European Radiology; vol. 13; pp. 863-866; 2003.

Yurdumakan B., et al.; 'Synthetic Gecko Foot-Hairs from Multiwalled Carbon Nanotubes'; The Royal Society of Chemistry; p. 3799-3801; 2005.

* cited by examiner




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A








FIG. 3B

**FIG. 4A**

**FIG. 4B**

**FIG. 5****FIG. 6**

ELECTRONICALLY ENHANCED ACCESS PORT FOR A FLUID FILLED IMPLANT

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/873,096, filed Aug. 31, 2010, which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/330,266, filed on Apr. 30, 2010, the entire disclosures of which are incorporated herein by reference.

FIELD

The present invention broadly relates to gastric bands and more specifically, to an electronically enhanced access port for a gastric band.

BACKGROUND

There are numerous varieties of fluid filled surgical implants presently comprising, or which may in the future comprise, access ports, for hydraulically adjustable gastric bands.

An exemplary hydraulic adjustable gastric band comprises a saline solution inside of one or more inflatable portions (e.g., silicone shells) positioned on the stomach surface of the ring of the gastric band to adjust the gastric band through a variety of diameters. As the inflatable portion is inflated it reduces the stoma of the gastric band and when the inflatable portion is deflated it increases the stoma of the gastric band. The saline solution is added to or removed from the inflatable portion via an access port fixed beneath the skin of the patient in the abdomen on the rectus muscle sheath using a fine needle to find the right level of restriction.

An exemplary gastric band (hydraulic, hydraulic-mechanical hybrid, or otherwise) may additionally, or alternatively, comprise an access port coupled with an override mechanism to rapidly remove fluid or gel from the implant in the event of an emergency.

Each of the foregoing implants, as well as others, comprise access ports that may be candidates for various electronics based enhancements, e.g., an access port fitted with a pressure sensor and/or an access port that transmits a signal for easier detection of its location within the body of the patient.

By way of example of the latter, it is essential with a hydraulic adjustable gastric band that the orientation of the implanted access port allows fluidic contact with the Huber needle of the syringe. In other words, the septum of the implanted access port should ideally be parallel to the plane defined by the surface of the patient's skin above the septum of the implanted access port. However, it is possible for the implanted access port to tilt from the ideal orientation resulting in less surface area for fluidic contact with the Huber needle. Thus, there is a need for tilt detection, communication, and compensation for fluid filled surgical implants.

Ferreri et al. (U.S. Pat. No. 7,658,196) discloses a system operable to detect the orientation of an implant component. Ferreri discloses that a sense head can be moved around a patient's body to determine a location of the implanted access port using, for example, triangulation. However, Ferreri does not disclose that the tilt detection occurs at the sense head by moving a sense head to a location of the center of the port. Thus, a user must scan a large area of the patient's body in order to determine the tilt of the implanted access port. This can be embarrassing to the patient, and inconvenient to the patient, and/or time consuming.

SUMMARY

In accordance with exemplary embodiments, the present invention provides for an electronically enhanced access port for a fluid filled implant. The access port may be used to connect to an implanted medical device, such as, a gastric band for the treatment of obesity, the gastric band may be suitable for laparoscopic placement around the stomach of a patient to create a stoma.

In accordance with exemplary embodiments, the present invention provides for an access port configured to detect the pressure of a fluid within the implant. In accordance with other exemplary embodiments, the present invention provides for an access port configured to detect its location within the body to facilitate a physician's access thereto.

In one embodiment, the present invention is an access port for a gastric band including a penetrable septum, a conduit configured to provide fluid communication between the penetrable septum and the gastric band, and an electronics based enhancement. The electronics based enhancement may be a pressure sensor or a tilt detector.

In another embodiment, the present invention is an access port for a gastric band including a penetrable septum, a conduit configured to provide fluid communication between the penetrable septum and the gastric band, and a pressure sensor in fluid communication with a fluid within the gastric band and configured to monitor a pressure of the fluid, generate a pressure value signal, and communicate the pressure value signal to an external control unit via RF telemetry.

In still another embodiment, the present invention is an access port for a gastric band including a penetrable septum, a conduit configured to provide fluid communication between the penetrable septum and the gastric band, and a tilt detector configured to detect a tilt datum indicating a tilt direction of the access port relative to body portions of the patient and a degree tilt of the access port relative to a surface of a skin of the patient.

BRIEF DESCRIPTION OF THE DRAWINGS

The exemplary embodiments of the present invention will be described in conjunction with the accompanying drawing FIGS. in which like numerals denote like elements and:

FIG. 1A illustrates an access port comprising a pressure sensor in accordance with an exemplary embodiment;

FIG. 1B illustrates a cross sectional view of an access port comprising a pressure sensor in accordance with an exemplary embodiment;

FIGS. 2A-2D illustrate tilt detection, communication, and compensation for exemplary implanted access port orientations in accordance with an exemplary embodiment;

FIG. 3A illustrates the components of an external control unit in accordance with an exemplary embodiment;

FIG. 3B illustrates the components of an implanted access port in accordance with an exemplary embodiment;

FIGS. 4A and 4B illustrate an exemplary method of tilt detection and communication in accordance with an exemplary embodiment;

FIG. 5 illustrates a process in accordance with an exemplary embodiment; and

FIG. 6 illustrates a process in accordance with an exemplary embodiment.

DETAILED DESCRIPTION

In accordance with exemplary embodiments, the present invention comprises an electronically enhanced access port

3

for a gastric band. Persons skilled in the art will readily appreciate that various aspects of the present invention may be realized by any number of methods and devices configured to perform the intended functions. Stated differently, other methods and devices may be incorporated herein to perform the intended functions. It should also be noted that the drawing FIGS. referred to herein are not all drawn to scale, but may be exaggerated to illustrate various aspects of the invention, and in that regard, the drawing FIGS. should not be construed as limiting. Finally, although the present invention may be described in connection with various medical principles and beliefs, the present invention should not be bound by theory.

By way of example, the present invention will be described primarily with reference to hydraulically adjustable gastric bands. Nevertheless, persons skilled in the art will readily appreciate that the present invention advantageously may be applied to one of the numerous varieties of fluid filled surgical implants presently comprising, or which may in the future comprise, access ports. Similarly, while the present invention will be described primarily with reference to fluid filled surgical implants, persons skilled in the art will readily appreciate that the present invention advantageously may be applied to other devices, and whether fluid or gel filled.

In accordance with exemplary embodiments, the present invention provides for an access port configured to detect the pressure of a fluid within the implant.

At the outset, it should be noted that while the present invention will be described primarily with reference to an access port, persons skilled in the art will readily appreciate that an access port is not necessary for detection of the pressure of a fluid within an implant. Stated differently, the diagnostic and therapeutic advantages associated with knowing the pressure of a fluid within an implant, as provided for by the present invention, may be realized without fluid access to the implant via an access port.

In exemplary embodiments, an access port comprises a sensor. The sensor can be in communication with an implant and configured to monitor a parameter of the access port. For example, the access port can be in communication with the fluid in the implant and can generate a pressure value signal based on the parameter and one or more parameter control limits. The parameter can be, for example, a pressure, a fill volume, a stress, a strain, a linear measurement of the implant, a force of the implant on the patient, and combinations thereof. The implant can be, for example, a gastric band.

In exemplary embodiments, the pressure sensor is coupled with a printed circuit board assembly (PCBA), which is in turn configured to telemetrically relay (e.g., via RF) a pressure value signal generated by the pressure sensor to an external control unit.

In exemplary embodiments, the pressure sensor and the PCBA are inductively powered, e.g., using an external magnetic field. In other embodiments, the pressure sensor and the PCBA are powered by one or more of a battery, rechargeable or otherwise, a capacitor, or a fuel cell. In accordance with various aspects of an exemplary embodiment, the power source is recharged by one or more of motion, a chemical change, or a temperature change. For example, in exemplary embodiments, the pressure sensor and the PCBA are powered by one or more of the following: (i) kinetic energy created by body motion stored onto a capacitor, (ii) an implanted fuel cell, (iii) an implanted power source powered by chemistry of the body, (iv) an implanted power source powered by temperature change, and (v) implanted batteries that can be recharged by direct contact or inductive coupling.

In exemplary embodiments, the pressure sensor, the PCBA and the power source are co-housed, while in other embodi-

4

ments, they are separately housed. By way of non-limiting examples, a hermetically sealed, self contained package may contain the PCBA and the power source, while a package comprising the pressure sensor, and necessary electronics and signal conditioning, can relay a pressure value signal to a separate package comprising the PCBA for conversion to an RF signal and telemetric relay to an external control unit. In this manner, the PCBA may be in direct contact with the fluid within the access port and the implant.

In accordance with one aspect of an exemplary embodiment, an access port comprising a pressure sensor further comprises an element structurally and/or spatially configured to guard the pressure sensor against a needle damaging it. In exemplary embodiments, the element is positioned between the access port septum and the pressure sensor, but other spatial configurations are contemplated. In exemplary embodiments, the element is housed separately from the PCBA so as to not interfere with telemetric relay of the RF signal to an external control unit.

Exemplary materials comprise titanium, stainless steel, ceramic and the like. That being said, persons skilled in the art will readily appreciate that any material which, by virtue of its thickness and/or hardness, is capable of guarding the pressure sensor against the needle damaging the pressure sensor, is suitable for use herein.

Turning now to FIGS. 1A and 1B, an exemplary access port 10 comprising a pressure sensor 20 is depicted. The access port 10 comprises a penetrable septum 30 through which fluid or gel is added to or removed from the access port 10 using a needle, and is thereby added to or removed from the fluid filled implant via a conduit 40. The needle can be, for example, a fine needle, a Huber needle, or any other type of needle which can supply fluid or gel to the access port 10. In addition, a tube, instead of a needle can be used. The access port 10 can be connected, for example, to a gastric band (not shown) and can be used to supply or remove fluid or gel from the gastric band. The access port 10 can also be connected, for example, to a breast implant (not shown) and can be used to supply or remove fluid or gel from the breast implant. In this embodiment, a plate element 50 is positioned between the penetrable septum 30 and the pressure sensor 20. The positioning of the plate element 50 serves to prevent the needle from damaging the pressure sensor 20. The plate element 50 can be formed, for example, from titanium, stainless steel, or any other type of material that can protect the pressure sensor 20 from damage.

The PCBA 60 can be connected, for example, to the pressure sensor 20. The PCBA 60 is configured to telemetrically relay a pressure value obtained from the pressure sensor 20 to an external control unit. The pressure value can indicate, for example, a pressure of the access port 10 and/or the gastric band. The pressure sensor 20 can also detect, for example, a fill volume, a strain, and/or a linear measurement of the access port 10. The access port 10 can also include, for example, a housing 70 which can, for example, define a cavity containing the pressure sensor 20, a portion of the conduit 40, the plate element 50, and/or the PCBA 60. The penetrable septum 30 can define, for example, an outer wall of the housing 70.

In accordance with exemplary embodiments, the present invention provides for an access port configured to detect its location within the body to facilitate a physician's access thereto. The location can be, for example, a relative location, or an exact location. In one embodiment, the access port 10 can be configured to determine the orientation of the implanted access port relative to the surface of the skin when a patient is in a known position, such as laying supine or standing vertically.

5

In exemplary embodiments, the access port **10** is configured to detect a tilt orientation of less than about 15 degrees, more preferably less than about 5 degrees, and most preferably less than about 1 degree.

In accordance with exemplary embodiments, the present invention utilizes electronics in the implanted access port and an external control unit to inductively power and control the implanted access port. In other embodiments, the implanted access port is powered by one or more of a battery, rechargeable or otherwise, a capacitor, and/or a fuel cell. In accordance with various aspects of an exemplary embodiment, the power source is recharged by one or more of motion, a chemical change, or a temperature change. For example, in exemplary embodiments, the implanted access port is powered by one or more of the following: (i) kinetic energy created by body motion stored onto a capacitor, (ii) an implanted fuel cell, (iii) an implanted power source powered by chemistry of the body, (iv) an implanted power source powered by temperature change, and/or (v) implanted batteries that can be recharged by direct contact or inductive coupling.

In accordance with exemplary embodiments, the external control unit uses RF telemetry to query the implanted access port for tilt information and then displays this information. Examples of display information are graphical, alpha-numeric such as a measure of tilt orientation in degrees, textual such as “flipped” versus “OK,” or a combination of these forms.

Once the tilt of the implanted access port relative to the surface of the skin above the implanted access port is known, then contacting the implanted access port with the Huber needle at a similarly matching tilt may, in some embodiments, help to compensate for the reduced surface area of the septum as compared to the ideal implanted access port orientation. Another embodiment of tilt compensation may be to manipulate the port by hand to reposition it closer to the ideal orientation. The following FIGS. illustrate tilt detection, communication, and compensation for exemplary implanted access port orientations.

FIG. 2A illustrates an implanted access port **110** oriented substantially parallel to a plane defined by the surface of the patient’s skin **120** above the implanted access port **110**. FIG. 2A also depicts a syringe **150** and a needle **152** of the syringe **150**. The needle **152** can be, for example, a Huber needle. Also shown are exemplary graphical and alpha-numeric displays **130** and **140**, respectively, for an external control unit (not shown) in accordance with exemplary embodiments. In one embodiment, a tilt detector may be located within the implanted access port **110** and/or the external control unit to determine tilt datum indicating the tilt of the implanted access port **110**. The tilt detector and/or the tilt datum can aid, for example, in generating the alpha-numeric displays **130** and **140**. The alpha-numeric display **130** can indicate, for example, a relative location of the implanted access port **110**.

The alpha-numeric display **130** can include, for example, an icon **132**. The icon **132** can indicate, for example, a tilt direction of the implanted access port **110** relative to body portions of the patient and a degree tilt of the implanted access port **110** relative to a surface of a skin of the patient. The degree tilt can be, for example, an amount of tilt of the implanted access port **110**. The tilt direction can be indicated by the location of the icon **132** relative to an intersection of the lines in the alpha-numeric display **130**. For example, angular measurements of the location of the tilt direction relative to the intersection of the lines in the alpha-numeric display **130** can indicate that the implanted access port **110** is tilted in a direction of the head of the patient, the left side of the patient, the right side of the patient, or the foot. The icon **132** can also

6

indicate the degree tilt of the implanted access port **110** through the location of the icon **132** relative to the intersection of the lines in the alpha-numeric display **130**. For example, the magnitude of the distance between the icon **132** and the intersection of the lines in the alpha-numeric display can indicate a degree tilt of the implant access port **110**. The icon **132** can also indicate whether the implanted access port **110** is non-flipped, or whether it has flipped.

In the non-flipped (or correct) position, a penetrable septum of the implanted access port **110** is facing or partially facing the skin **120**. In the flipped position, the penetrable septum is not facing the skin **120** such that it is not possible to contact the penetrable septum with the needle. While the orientation of the access port can sometimes be ascertained simply by sense of touch or the more involved use of fluoroscopy, there have been cases where a flipped port cannot be positively identified even with fluoroscopy. In FIG. 2A, the icon **132** indicates that the implanted access port **110** is not tilted. The white center in the icon **132** also indicates that the implanted access port **110** is in a non-flipped position.

Furthermore, the alpha-numeric display **140** can also include a degree indication **142** and a flipped indication **144**. The degree indication **142** can digitally numerically indicate, for example, a degree tilt of the implanted access port **110**. The flipped indication **144** can give, for example, an indication as to whether the implanted access port **110** has flipped or not. In FIG. 2A, the degree indication **142** indicates a 0 degree tilt while the flipped indication **144** indicates that the implanted access port **110** has not flipped. Thus, in FIG. 2A, no compensation with the syringe **150** and/or the needle **152** is required.

FIG. 2B therefore illustrates an implanted access port **110** flipped relative to the plane defined by the surface of the patient’s skin **120** above the implanted access port **110**. Again shown are exemplary graphical and alpha-numeric displays **130** and **140**, respectively, for an external control unit in accordance with exemplary embodiments. The degree indication **142** indicates that the implanted access port **110** has no tilt relative to the surface of the skin. The icon **132** in FIG. 2B is located at the intersection indicating no magnitude for the degree tilt, and thus indicates that the implanted access port **110** is not tilted. However, the lack of the white center in the icon **132** indicates that the implanted access port **110** has flipped. This is also confirmed by the flipped indication **144** indicating that the implanted access port **110** has flipped. In FIG. 2B, no compensation with the syringe **150** and/or the needle **152** is sufficient since the access port must be flipped back to its non-flip state before the syringe **150** and/or the needle **152** can be used to access the implanted access port **110**.

FIG. 2C illustrates an implanted access port **110** tilted to the patient’s left relative to the plane defined by the surface of the patient’s skin **120** above the implanted access port **110**. Again shown are exemplary graphical and alpha-numeric displays **130** and **140**, respectively, for an external control unit in accordance with exemplary embodiments. In FIG. 2C, the icon **132** indicates that the implanted access port **110** is tilted in a direction to the left side of the patient’s body at an approximately 20 degree angle. The 20 degree angle can be estimated based on the distance between the icon **132** and the intersection of the lines in the alpha-numeric display **130**. The icon **132** also indicates that the implanted access port **110** has not flipped. This is confirmed, for example, by the flipped indication **144**, which states that the implanted access port **110** has not flipped. Furthermore, in FIG. 2C, an arrow **146** in the alpha-numeric display **140** further indicates the tilt direction of the implanted access port **110**. Here, the arrow **146** is

pointed directly to the left indicating that the implanted access port is tilted towards a left side of the patient. The degree indication **142** also indicates that the implanted access port **110** is tilted at a 20 degree angle. Thus, compensation of approximately 20 degrees to the left side of the patient with the syringe **150** and/or the needle **152** is needed.

FIG. 2D illustrates an implanted access port **110** tilted to the patient's feet and right relative to the plane defined by the surface of the patient's skin **120** above the implanted access port **110**. Also shown are exemplary graphical and alpha-numeric displays, **130** and **140**, respectively, for an external control unit in accordance with exemplary embodiments. In FIG. 2D, the icon **132** indicates that the implanted access port **110** is tilted towards the right side of the patient's body and the patient's foot. Based on the distance between the icon **132** and the intersection of the lines in the alpha-numeric display **130**, a degree tilt of 30 degrees relative to the surface of the skin of the patient can be estimated. The icon **132** indicates that the implanted access port **110** is not flipped. This is confirmed, for example, by the arrow **146** and the flipped indication **144**. Furthermore, the degree indication **142** digitally numerically indicates that the implanted access port **110** is tilted at a 30 degree angle. Thus, compensation of approximately 30 degrees generally to the right side of the patient's body and the patient's foot with the syringe **150** and/or the needle **152** is needed.

With reference now to FIGS. 3A and 3B, an exemplary external control unit **301** comprises a micro-controller **310** that manages the various functions of the external control unit **301**. The micro-controller **310** interfaces to an inductive coil driver **320** that sends RF energy to an exemplary implanted access port **302** via a loop antenna **325**. The inductive coil driver **320** in exemplary embodiments comprises semiconductor switches such as transistors or field effect transistors, and it drives a coil that is tuned to the proper frequency using RF tuning capacitors. A frequency generator **330** creates the proper frequency for the inductive coil driver **320**. An RF radio **340** passes data to and from the micro-controller **310** and communicates with a matching implanted access port RF radio **380**.

A graphic display and user interface **350** are connected to the micro-controller **310** and provide information to and from the operator of the external control unit **301**. The graphic display is, in an exemplary embodiment, a color touch screen liquid crystal display (LCD). The user interface is, in an exemplary embodiment, also a color touch screen LCD, and may further comprise buttons, voice recognition, buzzer, speaker, switches, keyboard, trackball, touch tablet, and other similar human interface devices.

Turning now to FIG. 3B, the implanted access port **302** comprises an inductive coil tuned circuit, further comprising a loop antenna **360** and low loss RF tuning capacitors that supply power to an inductive power conversion circuit **365**. The inductive power conversion circuit **365** transforms the input RF energy to DC energy for use by the implanted access port **302** electronics utilizing a bridge rectifier, filtering capacitors, and a voltage regulator. It is also possible to use an implanted battery or other external or internal energy source. Typical inductive powering RF frequencies can be approximately 125 kHz, 6.75 MHz, or 27 MHz. The voltage regulator can be a switch mode power supply or linear regulator depending on voltage levels and efficiency requirements. Typical voltage levels can range from 1 volt to 20 volts. The inductive power conversion circuit **365** in exemplary embodiments has one or more protection mechanisms such as over temperature and over voltage shut down.

A micro-controller **370** is used to execute software that performs the various functions of the implanted access port **302**. Examples of suitable micro-controllers **370** are the Texas Instrument® MSP430 or CC430 series, Atmel AT32 L series, Freescale Coldfire series, and similar commercially available devices.

The RF radio **380** interfaces with the micro-controller **370** to transmit and receive data to and from the external control unit **301**. A preferred frequency range for RF radio **380** is in the Medical Implant Communications Service (MICS) frequency band of approximately 402 MHz to 405 MHz. Examples of applicable radio devices are the Texas Instruments® CC1101, Atmel ATA542X series, Microchip MRF49XA, and similar commercially available devices. The micro-controller **370** monitors the input voltage to ensure that it is within a predetermined range and communicates with external control unit **301** if changes to the input voltage of the implanted access port **302** are necessary. Furthermore, the micro-controller **370** in the implanted access port **302** can communicate with the micro-controller **310** in the control unit **301** to increase or decrease an amount of energy supplied to the implanted access port **302** in order to maintain optimal operating conditions. Such monitoring can occur at regular intervals.

A 3-axis accelerometer **390** can be used to sense a tilt of the implanted access port **302** based on its orientation relative to gravity and interfaces to the micro-controller **370** to provide tilt information. Examples of the 3-axis accelerometer **390** are the Analog Devices ADXL335, Freescale MMA7660FC, and similar commercially available devices.

In exemplary embodiments, the implanted access port **302** is contained within a housing. In one embodiment, the external control unit **301** and/or the implanted access port **302** can detect when a syringe and/or a needle of the syringe has contacted the implanted access port **302**. For example, the implanted access port **302** can detect vibration data and transmit such vibration data to the external control unit **301**. The external control unit **301** can analyze the vibration data to determine whether the vibration data indicates that the syringe and/or the needle of the syringe has contacted the implanted access port **302**.

In another embodiment, the external control unit **301** and/or the implanted access port **302** can detect when the syringe and/or the needle of the syringe has entered or been inserted into the implanted access port **302**. For example, a user can move the syringe and/or the needle of the syringe when it is believed to have entered the implanted access port **302**. The user can then see if a corresponding tilt of the implanted access port **302** is displayed on the external control unit **301**. If tilting the syringe and/or the needle of the syringe causes the implanted access port **110** to tilt, then it is likely that the syringe and/or the needle of the syringe is inserted into the implanted access port **110**. However, if tilting the syringe and/or the needle of the syringe does not cause the implanted access port **110** to tilt, then it is likely that the syringe and/or the needle of the syringe is not inserted into the implanted access port **110**.

In exemplary embodiments, in order to accurately and precisely measure the tilt angle, the implanted access port **110** is implanted in the same orientation each time. Otherwise, head-to-foot and right-to-left references may be incorrect. In other exemplary embodiments, the patient may be asked to roll to the right, then roll to the left, then sit up, all from a supine position while "training" the external control unit to learn the implanted access port tilt directions. In yet other exemplary embodiments, only whether the implanted access port has flipped is measured by the implanted access port **110**.

FIGS. 4A and 4B depict an exemplary method of tilt detection and communication. First, the physician turns on the external control unit (step 402). The external control unit in turn initializes (step 404) and informs the physician to place the external control unit inductive coil next to the patient's implanted access port (step 406). Once there is sufficient inductive energy coupling between the external control unit and the implanted access port (step 408), the implanted access port signals the external control unit that it is powered up along with any other identifying, diagnostic, initialization, or other such information (step 410). It is possible that too much or too little energy can be coupled so the implanted access port monitors this condition (step 412) and if there is an incorrect power (step 414), a radio link can be used to communicate with the external control unit to decrease or increase the coil drive (step 416). In exemplary embodiments, the voltage monitoring function occurs at regular intervals to maintain optimal operating conditions (step 420).

After the optimal operating conditions have been established, the tilt information from the implanted access port is passed to and displayed on the external control unit (step 426). The communication protocol to pass tilt information between the implanted access port and the external control unit can be implemented in any practical form. For example, one embodiment is to have the implanted access port stay in a low power, or idle mode (step 418) and go to initialization, diagnostics, tilt measurement, voltage measurement, temperature measurement, radio communication or other higher power modes (step 424) only when requested to do so by the external control unit (step 422). This communication protocol is advantageous because the implanted access port is primarily in a low power, or idle mode thereby minimizing implant heating. Another embodiment is to have the implanted access port go to initialization, diagnostics, tilt measurement, voltage measurement, temperature measurement, radio communication or other higher power modes only at regular intervals determined by the implanted access port.

At this point, the physician can act on implanted access port tilt information that has been conveyed through the external control unit (step 428). If the implanted access port is within a reasonable tilt angle, access thereto can proceed normally. However, if the implanted access port indicates that it is in a flipped position, then the physician can act accordingly such as further analysis by fluoroscopy. The external control unit is finally powered down (step 430).

Advantageously the present invention allows a determination of whether the access port 110 has flipped without resorting to the inherent risks of ionizing radiation, potentially error prone interpretation, and time consuming process of fluoroscopy. In addition, the reporting of the tilt angle allows for an adjustment of the angle of the access port 110 and/or the Huber needle in order to compensate for the associated reduction in exposed septum area.

In one embodiment, the present invention is a process shown in FIG. 5. In Step S502, vibration data is detected using the implanted access port. For example, the implanted access port 302 can detect vibration data and transmit such vibration data to the external control unit 301. In Step S504, the vibration data can be analyzed to determine whether the syringe has contacted the implanted access port. For example, the external control unit 301 can analyze the vibration data to determine whether the vibration data indicates that the syringe and/or the needle of the syringe has contacted the implanted access port 302.

In another embodiment, the present invention is a process shown in FIG. 6. In Step S602, a needle of the syringe is tilted. For example, a user can move the syringe and/or the needle of

the syringe when it is believed to have entered the implanted access port 302. In Step S604, tilt datum of the implanted access port is determined. For example, the tilt datum of the implanted access port 302 can be analyzed.

In Step S606, the tilt datum is analyzed to determine whether the implanted access port is tilted when the needle of the syringe is tilted. For example, the user can then see if a corresponding tilt of the implanted access port 302 is displayed on the external control unit 301. If tilting the syringe and/or the needle of the syringe causes the implanted access port 110 to tilt, then it is likely that the syringe and/or the needle of the syringe is inserted into the implanted access port 110. However, if tilting the syringe and/or the needle of the syringe does not cause the implanted access port 110 to tilt, then it is likely that the syringe and/or the needle of the syringe is not inserted into the implanted access port 110.

The foregoing disclosure is illustrative of the present invention and is not to be construed as limiting the invention. Although one or more embodiments of the invention have been described, persons skilled in the art will readily appreciate that numerous modifications could be made without departing from the spirit and scope of the present invention. It should be understood that all such modifications are intended to be included within the scope of the invention.

The terms "a," "an," "the," and similar referents used in the context of describing the present invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate the present invention and does not pose a limitation on the scope of the present invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the present invention.

Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements

11

in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Furthermore, certain references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.

Specific embodiments disclosed herein may be further limited in the claims using consisting of or consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.

In closing, it is to be understood that the embodiments of the present invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the present invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

What is claimed is:

1. An access port for connecting to a gastric band for the treatment of obesity, the gastric band suitable for laparoscopic placement around the stomach of a patient to create a stoma, the access port comprising:

a housing defining a cavity and comprising a penetrable septum defining an outer wall of the housing;
a conduit configured to carry fluid between the penetrable septum and an inflatable portion of the gastric band; and
a tilt detector coupled to the housing and configured to determine a tilt direction of the housing relative to at least one body portion of the patient including head, left side, right side, and foot, and to detect whether or not the housing is flipped away from the surface of the skin of the patient, wherein an external control unit is configured to communicate with the tilt detector and, based on the communication, the external control unit is configured to display a tilt datum and an indicator of whether or not the housing is tilted in a direction of at least one of the patient's head, left side, right side, and foot.

2. The access port of claim 1, wherein the tilt detector is a 3-axis accelerometer.

3. The access port of claim 1, wherein the gastric band is a hydraulically adjustable gastric band.

4. The access port of claim 1, wherein the tilt detector is further configured to communicate the tilt datum to the external control unit via RF telemetry.

5. The access port of claim 1, wherein the tilt detector is powered by kinetic energy created by body motion stored onto a capacitor.

6. The access port of claim 1, wherein the tilt detector is powered by an implanted fuel cell.

7. The access port of claim 1, wherein the tilt detector is powered by an implanted power source powered by chemistry of the body.

8. The access port of claim 1, wherein the tilt detector is powered by an implanted power source powered by temperature change.

9. The access port of claim 1, wherein the tilt detector is powered by implanted batteries that can be recharged by direct contact.

12

10. The access port of claim 1, wherein the tilt detector is inductively powered.

11. The access port of claim 1, further comprising a sensor located in the housing, the sensor detecting a parameter.

12. The access port of claim 11, wherein the parameter is selected from a group consisting of a pressure, a fill volume, a stress, a strain, a linear measurement, and combinations thereof.

13. The access port of claim 11, wherein the sensor is a pressure sensor.

14. The access port of claim 13, further comprising a plate element positioned between the penetrable septum and the pressure sensor to guard the pressure sensor against a needle damaging it.

15. An access port for connecting to a gastric band for the treatment of obesity, the gastric band suitable for laparoscopic placement around the stomach of a patient to create a stoma, the access port comprising:

a penetrable septum defining an outer wall of a housing;
a conduit configured to carry fluid between the penetrable septum and an inflatable portion of the gastric band; and
a tilt detector coupled to the housing and configured to detect a tilt direction of the housing relative to at least one body portion of the patient including head, left side, right side, and foot, and to detect a degree tilt of the housing relative to a surface of a skin of the patient, and to detect whether or not the housing is flipped away from the surface of the skin of the patient, wherein an external control unit is configured to communicate with the tilt detector and, based on the communication, the external control unit is configured to display a tilt datum and an indicator of whether or not the housing is tilted in a direction of at least one of the patient's head, left side, right side, and foot.

16. The access port of claim 15, further comprising a pressure sensor in fluid communication with a fluid within the gastric band and configured to monitor a pressure of the fluid and generate a pressure value signal.

17. An access port for connecting to a gastric band for the treatment of obesity, the gastric band suitable for laparoscopic placement around the stomach of a patient to create a stoma, the access port comprising:

a penetrable septum defining an outer wall of a housing;
a conduit configured to provide fluid communication between the penetrable septum and the gastric band; and
a tilt detector coupled to the housing and configured to detect a tilt datum indicating a tilt direction of the access port relative to at least one body portion of the patient including head, left side, right side, and foot, and a degree tilt of the access port relative to a surface of a skin of the patient, and to detect whether or not the housing is flipped away from the surface of the skin of the patient, wherein an external control unit is configured to communicate with the tilt detector and, based on the communication, the external control unit is configured to display a tilt datum and an indicator of whether or not the housing is tilted in a direction of at least one of the patient's head, left side, right side and foot.

18. The access port of claim 17, wherein the external control unit is configured to receive via RF telemetry the tilt datum and a location of the access port and to display the tilt datum and a location of the access port.

19. The access port of claim 17, wherein the tilt detector is a 3-axis accelerometer.

20. A method of determining an insertion of a needle of a syringe into an implanted access port comprising:

13

providing an external control unit to wirelessly communicate with the implanted access port through tissue of a patient in which the access port is implanted;
 inserting the needle of the syringe into a patient;
 tilting the inserted needle of the syringe;
 determining, with the external control unit, a tilt datum of the implanted access port;
 analyzing, with the external control unit, the tilt datum to determine whether the implanted access port is tilted in response to tilting the needle of the syringe;
 determining, with the external control unit, that the needle of the syringe is inserted into the access port if it is determined that the access port is tilted in response to tilting the needle of the syringe; and
 determining, with the external control unit, that the needle of the syringe is not inserted into the access port if it is determined that the access port is not tilted in response to tilting the needle of the syringe.

21. A system for determining an insertion of a needle of a syringe into an implanted access port comprising:
 an implanted access port having a housing defining a cavity, the housing comprising a penetrable septum defining an outer wall of the housing and a tilt detector coupled to the housing and configured to determine a tilt direction of the housing relative to at least one body portion of the patient; and

14

an external control unit in wireless communication with the implanted access port, the external control unit comprising a processor and a non-transitory processor-readable storage medium storing a program for causing the processor to execute a method for determining an insertion of a needle of a syringe into the implanted access port, the method comprising:
 wirelessly communicating with the implanted access port through tissue of a patient in which the access port is implanted and in which the needle of the syringe is inserted into a patient;
 determining a tilt datum of the implanted access port based on data received from the implanted access port;
 analyzing the tilt datum to determine whether the implanted access port is tilted in response to tilting the needle of the syringe;
 determining that the needle of the syringe is inserted into the access port if it is determined that the access port is tilted in response to tilting the needle of the syringe; and
 determining that the needle of the syringe is not inserted into the access port if it is determined that the access port is not tilted in response to tilting the needle of the syringe.

* * * * *